FAST MONEY FEATURES
FAST MONEY POLLGet in the post game. Respond to our
"Question of the Day" right now.
TRADER RADAR Which stock should be on your screen? Follow the clues to solve this puzzle.
TRADE SCHOOLGrab a pencil because school is in session and the Fast Money traders are teaching class.
EMERGING MONEY TOP 20
Fast Money's index for the world.
FAST MONEY PODCASTSDownload Fast Money onto your MP3 Player.
FAST MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
SHOP FOR FAST MONEY MERCHANDISEGet your game on with Fast Money gear.
FAST MONEY PHOTOS!Check out our scrapbook. These "pix" are guaranteed winners.
NEWSLETTERSign up and receive a recap email every Friday after the show!
FAST MONEY MOBILE ALERTSGet advanced information about the next Fast Money.
Text Size 
 |
Eli Lilly CEO John Lechleiter joined the traders on Fast Money. Following is a synopsis of what was said.
Q: What’s going on with your stock?
A: “In the first 7 months of the year the the Amex Pharmaceutical Index [PPH
Loading...
()
] and Lilly [LLY
Loading...
()
] have outperformed the S&P,” explains Lechleiter, “so I think there is an element of safety seeking here and if you look at the average dividend yields we’re up about 100 basis points relative to the dividend you see across the broader index.”
Q: What are your expectations for profits from your pipeline?
“The results we reported for Q2 in July featured 21% sales growth from the 9 products that we’ve introduced this decade,” replies Lechleiter. “So as we look ahead we expect to see further growth from new indications, line extensions and just untapped potential of our product portfolio.”
"Beyond that on September 26th we expect to hear back about prasugrel. The trade name will be known as Effient, which is our cardiovascular drug. (Also) we have a pipeline that features a new bone drug and we have a once a week version of our popular diabetes drug Byetta. And last week at the Alzheimer’s meeting we announced that we’re going to be the only company with 2 potential Alzheimer’s treatments in Phase 3 studies.”
Q: Is there any need for acquisition?
”As we look at licensing deals and smaller acquisitions we look at them in a way that brings us some new innovation that can have some benefit for us in the 2011, 2012, and 2013 time period,” says Lechleiter. (In other words, explains Dylan Ratigan, Lilly would be looking to buy into a more advanced pipeline if that was available.)
Check Out These Other Posts |
______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to .
Trader disclosure: On Aug 12, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (MSFT), (WMT), (UUP), (EMC); Pete Najarian Owns (AAPL),(NVDA), (TSO); Pete Najarian Owns (CSCO) Calls; Jon Najarian Owns (C),(NVDA); Jon Najarian Owns (AAPL) Calls,(CSCO) Calls, (TSO) Calls; Jon Najarian Owns (GLD) Puts, Jon Najarian Owns (EEM) Puts; Terranova Owns (GS), (YHOO), (XLF), (INTC), (SU), (VLO), (SA), (BNI), (RIMM), (KOL), (CME), (GOOG), (IYT), (FCX); Terranova Is Short December 2008 Crude Oil; Terranova Is Long December 2012 Crude Oil;
Terranova Is Chief Alternatives Strategist Of Phoenix Investment Partners, Ltd.Phoenix Investment Partners Owns More Than 1% Of (ABD), (ARE), (BRE), (CNTY), (CLB), (OFC), (DLR), (ESS), (EXR), (FL), (IAT), (IGE), (LNET), (MAC), (OIIM), (PSPT), (DBC), (DBV), (SLB), (SKT), (BLV)
Terranova Is Co-Portfolio Manager Of The Phoenix Diversifier PHOLIO; Phoenix Diversifier PHOLIO Owns (IGE), (DBC), (DBV)
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes